Segall Bryant & Hamill LLC Has $7.09 Million Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Segall Bryant & Hamill LLC boosted its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 142.7% during the third quarter, Holdings Channel.com reports. The institutional investor owned 911,443 shares of the medical instruments supplier’s stock after acquiring an additional 535,958 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in AngioDynamics were worth $7,091,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of ANGO. Millennium Management LLC increased its holdings in shares of AngioDynamics by 41.9% in the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock valued at $10,850,000 after purchasing an additional 529,861 shares during the last quarter. Western Standard LLC grew its stake in AngioDynamics by 878.5% in the 1st quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock valued at $3,072,000 after buying an additional 469,906 shares during the last quarter. First Eagle Investment Management LLC bought a new position in AngioDynamics in the 2nd quarter valued at about $1,321,000. Systematic Financial Management LP lifted its position in AngioDynamics by 8.4% during the second quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock worth $12,763,000 after acquiring an additional 162,972 shares during the last quarter. Finally, Kennedy Capital Management LLC boosted its holdings in shares of AngioDynamics by 425.0% during the first quarter. Kennedy Capital Management LLC now owns 190,236 shares of the medical instruments supplier’s stock worth $1,117,000 after acquiring an additional 154,002 shares during the period. Institutional investors own 89.43% of the company’s stock.

Insiders Place Their Bets

In related news, CEO James C. Clemmer acquired 20,000 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were purchased at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the acquisition, the chief executive officer now owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. This trade represents a 3.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders acquired 22,568 shares of company stock worth $135,847. 5.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ANGO has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of AngioDynamics in a research note on Friday, October 4th. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th.

AngioDynamics Price Performance

Shares of NASDAQ ANGO opened at $6.95 on Friday. AngioDynamics, Inc. has a 1 year low of $5.26 and a 1 year high of $8.25. The firm has a market cap of $282.38 million, a PE ratio of -1.11 and a beta of 0.67. The company has a 50 day simple moving average of $6.97 and a 200 day simple moving average of $6.78.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The company had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $67.93 million. During the same quarter in the prior year, the firm posted ($0.12) earnings per share. The business’s quarterly revenue was down 14.2% on a year-over-year basis. As a group, research analysts anticipate that AngioDynamics, Inc. will post -0.41 earnings per share for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.